We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking "Accept," you agree to our website's cookie use as described in our Privacy Policy.
ACCEPTDenyPREFERENCES
+

Link to Healthcare Professionals Site

The information contained in this section is intended for U.S. healthcare professionals only.

Enter the SiteCancel
+

Link to Healthcare Professionals Site

The information contained in this section is intended for U.S. healthcare professionals only.

Enter the SiteCancel
+

Find a Prescriber Near You

* Intended for US residents only
Thank you!

We will contact you promptly.
Oops! Something went wrong while submitting the form.

Contact a Luminopia Representative

Provider Type*
Intended for US healthcare providers only. Your information will not be shared with anyone else.
Thank you!

We will contact you promptly.
Oops! Something went wrong while submitting the form.

Beyond the Patch

The only FDA-cleared amblyopia treatment with comparable efficacy in older and younger children previously treated for amblyopia1-3

Contact a rep to Learn More

What is Luminopia?

As we all know, many children still have amblyopia even after months to years of treatment.4,5 Patching has been shown to be even less effective in older kids.6 Now you have another option.
‍
Luminopia is a clinically proven treatment for amblyopia patients ages 4-12 to achieve vision gains beyond conventional therapy.1-3

Demonstrated comparable vision gains in previously treated, older children2

In the real-world PUPiL registry*, children ages 4-7 and 8-12, who were previously treated for years, gained an average of 1.2 lines of BCVA.2

Visual acuity improvement by age group

Key Findings
  • Previously treated population: average duration of prior treatment was 2.4 years
  • Older kids gained as much vision as younger kids, even though research demonstrates conventional treatment is less effective at ages 8-12.6
  • Older children can be treated with the same expectation of response as younger children

p<0.001 for improvement from baseline. LS Mean and 95% CI, adjusted for baseline acuity. PUPiL Registry (NCT06429280). Data on file.

Contact a rep to Learn More

A proven treatment option for 1,500+ prescribers

Photo of girl wearing Luminopia VR headset

“I like to tell families that since this treatment works differently, it could work well for your child—even if they’ve tried other treatments before that have failed.”

Eric Gaier, MD, PhD

Pediatric Neuro-Ophthalmologist and Adult Strabismus Surgeon, Boston Children’s Hospital; Assistant Professor of Ophthalmology, Harvard Medical School.

Contact a rep to Learn More

How Luminopia works

Our unique, dual-acting mechanism encourages both eyes to work together to help improve vision. Luminopia modifies popular TV shows in real time, inside a lightweight, immersive VR headset.

Reducing contrast

to the stronger eye overcomes suppression of the amblyopic eye7

Dichoptic masking

blocks complementary parts of the image for each eye to encourage the brain to combine the video into one complete image8

Contact a rep to Learn More

Luminopia works for your practice and for your families

Only 1 hour a day, 6 days a week1

Clinical trial demonstrated 85% compliance with prescribed treatment3

Significant vision improvement at 12 weeks1,3**

Prescribe in minutes

Contact a Luminopia Representative

Provider Type*
Intended for US healthcare providers only. Your information will not be shared with anyone else.
Thank you!

We will contact you promptly.
Oops! Something went wrong while submitting the form.
Indication
Luminopia is indicated for improvement in visual acuity in amblyopia patients age 4 to <13, associated with anisometropia and/or with mild strabismus. Luminopia is intended to be used as an adjunct to full-time refractive correction, in an at-home environment, and is for Prescription Use Only.
Safety
  • No serious adverse events* reported with Luminopia
  • Most common adverse event reported (treatment vs. control): Headaches (14.3% vs. 1.7%), all graded as mild and transient
  • Cases of new or worsening heterotropia were balanced between groups (7.1% vs. 8.5%)
  • Rate of all ocular adverse events similar between groups. *Includes events classified with possible, probable, or definite relation to study treatment
  • Safety of Luminopia in children aged 8-12 is expected to be in line with the safety in children aged 4-7

Important Information About Luminopia
  • Patients should only use Luminopia while wearing their prescribed refractive correction under the headset
  • Patients should wear Luminopia while seated or lying down
  • Additional evaluation may be required for patients with a history of light-induced seizures, serious medical conditions, new or worsening eye-turn, or double vision
  • Patients should stop using Luminopia and contact you for additional evaluation if they experience worsening vision in either eye, headache, nausea, eye strain that doesn’t go away after usage, dizziness, or increased night terrors

*PUPiL Registry Overview
  • The PUPiL Registry is designed to collect real-world data from a diverse group of patients that have been prescribed Luminopia
  • Patient demographics and ocular history retrospectively collected
  • Vision outcomes collected at follow-up visit while on Luminopia and for a year after stopping Luminopia
  • All treatment decisions are at the discretion of the clinician
  • Patient cohort selected for analysis include: any patient in the Registry who has completed treatment with a follow-up visit +/- 6 weeks of the last date of treatment age 4-12 years, with unilateral anisometropic / strabismic amblyopia, defined as 2 or more lines interocular difference with 20/40 or worse in the amblyopic eye
References
  • Luminopia. Directions for Use, LBL-0001 Rev E. Luminopia, Inc.; 2025.
  • Real-world outcomes from the PUPiL Registry (NCT06429280) in patients aged 4 to 7 years vs patients aged 8 to 12 years. Data on file.
  • Xiao S, Angjeli E, Wu HC, et al; Luminopia Pivotal Trial Group. Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia. Ophthalmology. 2022;129(1):77-85.
  • Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, et al. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol. 2008;126(8):1039-1044. doi:10.1001/archopht.126.8.1039
  • Birch EE, Kelly KR. Amblyopia and the whole child. Prog Retin Eye Res. 2023;93:101168. 

    doi:10.1016/j.preteyeres.2023.101168
  • Holmes JM, Lazar EL, Melia BM, et al; Pediatric Eye Disease Investigator Group. Effect of age on response to amblyopia treatment in children. Arch Ophthalmol. 2011;129(11):1451-1457. doi:10.1001/archophthalmol.2011.179
  • Li J, Thompson B, Lam CS, et al. The role of suppression in amblyopia. Invest Ophthalmol Vis Sci.
    2011;52(7):4169-4176.
  • Birch EE, Jost RM, Wang YZ, Kelly KR, Giaschi DE. Impaired Fellow Eye Motion Perception and Abnormal

    Binocular Function. Invest Ophthalmol Vis Sci. 2019;60(10):3374-3380
**Change in amblyopic BCVA at 12 weeks was 1.81 lines with Luminopia vs 0.85 lines with glasses alone.
LUM-0262